^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide

Excerpt:
Loss of MSH2 and MSH 6 was observed in a single patient who had a rapid development of resistance to TMZ.
DOI:
10.1210/jc.2014-4350